International Journal of Nanomedicine (Feb 2021)
Nanozymes as Enzyme Inhibitors
Abstract
Yaling Huang,1 Jian Jiang,1 Yanqiu Wang,1 Jie Chen,1 Juqun Xi1,2 1Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu, 225001, People’s Republic of ChinaCorrespondence: Juqun XiInstitute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of ChinaTel +86 0514-87978804Fax +86 0514-87341733Email [email protected]: Nanozyme is a type of nanomaterial with intrinsic enzyme-like activity. Following the discovery of nanozymes in 2007, nanozyme technology has become an emerging field bridging nanotechnology and biology, attracting research from multi-disciplinary areas focused on the design and synthesis of catalytically active nanozymes. However, various types of enzymes can be mimicked by nanomaterials, and our current understanding of nanozymes as enzyme inhibitors is limited. Here, we provide a brief overview of the utility of nanozymes as inhibitors of enzymes, such as R-chymotrypsin (ChT), β-galactosidase (β-Gal), β-lactamase, and mitochondrial F0F1-ATPase, and the mechanisms underlying inhibitory activity. The advantages, challenges and future research directions of nanozymes as enzyme inhibitors for biomedical research are further discussed.Keywords: nanozyme, R-chymotrypsin inhibitor, β-galactosidase inhibitor, β-lactamase inhibitor, mitochondrial F0F1-ATPase inhibitor
